转酶1通过代谢重编程和自-溶解体通路影响帕金森病的发病
Zixin Tan1, Huimin Hu1, Hao Chen1
1Department of Neurology, The First Affiliated Hospital of Guangzhou Medical University, No. 151 Yanjiang Road, Guangzhou, 510120, China.
Acta neuropathologica communications
|November 4, 2025
概括
向Transaldolase1 (TAL1) 显示出对帕金森病 (PD) 治疗的前景. 抑制TAL1可以增强自 - lysosomal功能和能量代谢,减少神经退行和α-synuclein聚合在PD模型.
科学领域:
- 神经科学是一个神经科学.
- 生物化学 生物化学
- 代谢途径 代谢途径
背景情况:
- 帕金森病 (PD) 涉及多巴胺基神经退行和α-synuclein聚合,与代谢问题和受损的自 - lysosomal路径 (ALP) 相关.
- 酸通路酶TAL1 (transaldolase1) 在PD黑色物质中升高,但其作用尚不清楚.
研究的目的:
- 为了研究TAL1在帕金森病的发病过程中的功能作用.
- 在PD模型中探索TAL1对神经退行,自和能量代谢的影响.
主要方法:
- 利用MPTP诱导和AAV-A53T的帕金森病小鼠模型.
- 进行了TAL1敲击实验和向的代谢学.
- 评估了自-溶酶体通路激活,AMPK/mTORC1信号传递,以及神经行为结果.
主要成果:
- 在两种PD模型中,TAL1上调与多巴胺能神经元损失相关.
- 抑制TAL1激活了TFEB介导的自酶体基因转录和调节的TCA循环/糖解.
- 神经保护通过AMPK/mTORC1通路激活,改善运动功能和降低基α-synuclein水平.
结论:
- 在实验性PD中,TAL1充当了自酶体功能和能量代谢的调节者.
- 抑制TAL1通过增强的自和代谢重编程恢复α-synuclein降解.
- 准TAL1为帕金森病提供了潜在的治疗策略.
更多相关视频
06:07Author Spotlight: Establishing a New Fluorescence-Based Protocol for In Vivo Mitochondrial Morphology Analysis in Parkinson's Disease
Published on: June 23, 2023
2.2K
14:45Analyzing the Parkinson's Disease Mouse Model Induced by Adeno-associated Viral Vectors Encoding Human α-Synuclein
Published on: July 29, 2022
6.5K
相关概念视频
Parkinson's Disease: Overview
1.7K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.7K
Lysosomal Hydrolases
4.4K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
4.4K
Parkinson's Disease: Treatment
963
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
963
Drugs Affecting Neurotransmitter Synthesis
2.1K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
2.1K
